In summary, we systematically evaluated the efficacy and safety of Trastuzumab deruxtecan in patients with HER2 + or HER2 low-expressing breast cancer, and also explained the reasons for the increased incidence of some adverse events, which provides an evidence-based basis for the monitoring of the drug use. Here, ERBB2 is linked to breast carcinoma.